Native aortic valve endocarditis with Morganella morganii in a patient with multiple myeloma and valvular amyloidosis: a case report

Patients with multiple myeloma (MM) are known to be immune incompetent and experience higher incidences of infectious diseases. However, infective endocarditis (IE) is rarely observed in patients with MM and Morg...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case report Source Type: research

Related Links:

Publication date: Available online 9 December 2019Source: Journal of American Association for Pediatric Ophthalmology and StrabismusAuthor(s): Mary-Magdalene Ugo Dodd, Natalie Wolkow, Mary Elizabeth Cunnane, Lina Ma, Thaddeus P. Dryja, David Hunter
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - Category: Opthalmology Source Type: research
Publication date: Available online 10 December 2019Source: Canadian Journal of CardiologyAuthor(s): Margot K. Davis, Nowell M. FineAbstractRecent developments in cardiac amyloidosis have raised awareness of the disease and have advanced diagnostic and treatment strategies. Novel therapies may vastly improve the prognosis of the disease but will be associated with significant costs. Data are needed to inform clinical decisions and to drive resource allocation within the health care system. Many aspects of disease management are unlikely to be addressed by clinical trials and better suited to non-randomized cohort studies, b...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Roy M. John, David L. SternAbstractArrhythmias are a major cause of morbidity and mortality in the course of cardiac amyloidosis (CA). Less commonly, they may be the initial manifestation that lead to the diagnosis. With improved therapeutic interventions for amyloidosis, it is no longer considered a terminal untreatable condition and there is an increasing recognition of the role of cardiac implantable electronic devices in CA. The frequency and nature of arrhythmias is largely determined by the type of amyloidosis. Bradyarr...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Eli Muchtar, Grace Lin, Martha GroganAbstractLight chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most commonly involved organ and the leading determinant of short and long-term survival. Pathogenic free light chains, fragments of intact immunoglobulins, are the amyloidogenic protein and are secreted by clonal bone marrow plasma cells. The goal of therapy is to cut-off the supply of these pathogenic light chains to allow organ r...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
ConclusionsThe findings of this study support the usefulness of PET/CT in the detection of subcutaneous MZL, and in staging and treatment decisions.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switchin...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Condition:   Relapsed or Refractory Multiple Myeloma Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Pomalidomide Sponsor:   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   B-cell Non Hodgkin Lymphoma;   B-cell Acute Lymphoblastic Leukemia;   Multiple Myeloma Intervention:   Biological: Novel CAR-T Sponsors:   Timmune Biotech Inc.;   Hunan Provincial People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
C2N Diagnostics’s detection test for Alzheimer’s disease is showing off some strong data coming out of the 12th Annual Clinical Trials in Alzheimer’s Disease conference. The St. Louis-based company said results from a study show the Aptus-Aβ test strongly predicts the presence of brain amyloidosis in a diverse population. C2N Diagnostics said its blood-based in vitro diagnostic is being developed to predict amyloid PET scan results. It combines into a ratio, the concentration of amyloid beta (Aβ) isoforms Aβ42 and Aβ40 in ...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone· Data selected as a Late-Breaking Abstract at ASH 2019
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Amyloidosis | Endocarditis | Infectious Diseases | Infective Endocarditis | Myeloma